Key clinical point: Among patients with relapsing-remitting MS, depression increases the likelihood of having worse neurologic function 1 year later.
Major finding: In an adjusted model, MS patients with depression were more likely to have a 20% worsening in at least one neurologic performance measure at year 1, compared with MS patients without depression (OR, 1.31).
Study details: An analysis of data from approximately 2,400 patients in MS PATHS.
Disclosures: The presenting author had no disclosures. Two coauthors have consulted for and received research support from pharmaceutical companies. MS PATHS is supported by Biogen.
Feng JJ et al. ACTRIMS Forum 2020. Abstract P226.